<DOC>
	<DOC>NCT00932165</DOC>
	<brief_summary>The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.</brief_summary>
	<brief_title>Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin</brief_title>
	<detailed_description>All the patients whom an investigator prescribes the first Exemestane (Aromasin) should be registered.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Subjects with postmenopausal breast cancer (including ovariectomy etc.). Patients cannot be evaluated.For example, not administered Exemestane (Aromasin).</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>